Prasad S. Adusumilli, MD, FACS, FCCP
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Deputy Chief and Associate Attending, Thoracic Surgery
Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center
Director, Mesothelioma Program
Member, Exp. Therapeutics Center & Centers for Cell Engineering
Memorial Sloan-Kettering Cancer Center
My research focuses on tumor immunology, chimeric antigen receptor (CAR) T-cell therapy, and combination immunotherapy for thoracic cancers. Over the years, we have developed clinically-relevant mouse models and modeled biological therapies in these models. This research has yielded mechanistic data that has been translated and is now in CAR T-cell and combination immunotherapy clinical trials for patients with lung cancer, pleural mesothelioma, and breast cancer. Our ongoing research focuses on investigating immunotherapy efficacy in human ex vivo translational models.
Our laboratory research has been funded by federal agencies and foundations resulting in >60 grant awards to date totaling >$30MM to date. My research has progressed to clinical trials and >180 publications including in Cancer Discov, FASEB, J Clin Invest, J Clin Oncol, J Natl Cancer Inst, Nat Med, and Sci Transl Med. In addition to serving on medical journal editorial boards, I am the Deputy Editor for Molecular Therapy Oncolytics. I serve as a member of national peer-review committees including NCI, DoD, PCORI, National health institutions of Austria, Belgium, Ireland, Italy, Poland, Netherlands, Switzerland, and the United Kingdom. I am a member of the Fleischner Society and American Society of Clinical Investigation. I serve on international committees including the American Society of Cell and Gene Therapy, NCI thoracic cancers steering committee, International Association for the Study of Lung Cancer, and the American Association for Thoracic Surgery. In my laboratory, I mentor MDs, MD/PhDs, and PhDs in thoracic oncology research, including visiting scholars from international institutions.
Terms of Appointment: Sep 2018 - Aug 2020